Giampaolo Merlini
#103,886
Most Influential Person Now
Researcher
Giampaolo Merlini's AcademicInfluence.com Rankings
Giampaolo Merlinicomputer-science Degrees
Computer Science
#3746
World Rank
#3937
Historical Rank
Computational Linguistics
#249
World Rank
#253
Historical Rank
Machine Learning
#529
World Rank
#535
Historical Rank
Artificial Intelligence
#734
World Rank
#745
Historical Rank
Download Badge
Computer Science
Giampaolo Merlini's Degrees
- PhD Computer Science University of Milan
- Masters Computer Science University of Milan
- Bachelors Computer Science University of Milan
Similar Degrees You Can Earn
Why Is Giampaolo Merlini Influential?
(Suggest an Edit or Addition)Giampaolo Merlini's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
- International uniform response criteria for multiple myeloma (2006) (2014)
- Molecular mechanisms of amyloidosis. (2003) (1632)
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis (2005) (1202)
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (2018) (1197)
- Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis (2016) (1108)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
- New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. (2012) (693)
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010) (660)
- Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types (2009) (586)
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis (2018) (553)
- Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. (2013) (527)
- International uniform response criteria for multiple myeloma (2006) (519)
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 (2005) (491)
- Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines (2016) (468)
- Amyloidosis: pathogenesis and new therapeutic options. (2011) (449)
- Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis (2003) (442)
- Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis (2014) (437)
- Dangerous small B-cell clones. (2006) (421)
- Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. (2004) (395)
- Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee (2018) (370)
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. (2013) (351)
- A primer of amyloid nomenclature (2007) (344)
- Amyloid: Toward terminology clarification Report from the Nomenclature Committee of the International Society of Amyloidosis (2005) (339)
- Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis (2010) (337)
- International prognostic scoring system for Waldenstrom macroglobulinemia. (2009) (332)
- A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. (2014) (327)
- Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. (2015) (321)
- Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis (2012) (315)
- International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. (2013) (309)
- Diagnosis of monoclonal gammopathy of renal significance. (2015) (302)
- A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. (2015) (299)
- Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis (2012) (294)
- Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. (2008) (290)
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. (2003) (281)
- Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. (2010) (279)
- The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (279)
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (2016) (277)
- Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. (2006) (265)
- Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. (2019) (261)
- Removal of the N‐terminal hexapeptide from human β2‐microglobulin facilitates protein aggregation and fibril formation (2000) (254)
- Clinical aspects of systemic amyloid diseases. (2005) (243)
- Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. (2013) (238)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging (2019) (235)
- Systemic immunoglobulin light chain amyloidosis (2018) (231)
- Management of treatment-emergent peripheral neuropathy in multiple myeloma (2012) (229)
- Amyloid Fibril Protein Nomenclature - 2002 (2002) (221)
- Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. (2021) (217)
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (2013) (216)
- Systemic light chain amyloidosis: an update for treating physicians. (2013) (215)
- Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. (2009) (215)
- The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). (2005) (215)
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) (2014) (211)
- Immunoglobulin light chain amyloidosis (2014) (210)
- The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies (2004) (206)
- Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study (2019) (206)
- Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. (1995) (206)
- Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee (2020) (204)
- International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
- Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. (2009) (199)
- Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study (2012) (196)
- Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. (2007) (191)
- The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. (2010) (190)
- Eprodisate for the treatment of renal disease in AA amyloidosis. (2007) (183)
- Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability. (2000) (181)
- Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). (2013) (172)
- Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division Committee on Plasma Proteins (C-PP) (2007) (172)
- What is new in diagnosis and management of light chain amyloidosis? (2016) (171)
- Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium (2015) (168)
- Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. (2012) (163)
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. (2006) (161)
- Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. (2009) (161)
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. (2011) (159)
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. (2016) (157)
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models (2010) (156)
- Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. (2016) (153)
- Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel (2018) (152)
- Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. (2018) (151)
- Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis (2002) (150)
- A practical approach to the diagnosis of systemic amyloidoses. (2015) (143)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI EXPERT CONSENSUS RECOMMENDATIONS FOR MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: PART 1 OF 2-EVIDENCE BASE AND STANDARDIZED METHODS OF IMAGING. (2019) (141)
- A Partially Structured Species of β2-Microglobulin Is Significantly Populated under Physiological Conditions and Involved in Fibrillogenesis* (2001) (138)
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. (2021) (135)
- Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(λIII) as a new amyloid-associated germline gene segment (2002) (133)
- Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA. (2020) (133)
- Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue*S (2008) (133)
- Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach (2014) (132)
- Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis (2013) (131)
- Structure, function and amyloidogenic propensity of apolipoprotein A-I (2006) (130)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization (2019) (121)
- 4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters (2003) (121)
- Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. (2013) (119)
- A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. (1980) (116)
- A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. (2014) (115)
- Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. (2006) (115)
- Outrageous prices of orphan drugs: a call for collaboration (2018) (114)
- Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients (2014) (112)
- AA amyloidosis: basic knowledge, unmet needs and future treatments. (2012) (111)
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
- Treatment of cardiac transthyretin amyloidosis: an update. (2019) (110)
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy (2020) (109)
- Holter Monitoring in AL Amyloidosis: Prognostic Implications (2001) (109)
- Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis (2016) (107)
- Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (2021) (106)
- Study of prognosis in Waldenström's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. (1994) (106)
- Management of AL amyloidosis in 2020. (2020) (105)
- Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis (2013) (104)
- Differential diagnosis of monoclonal gammopathy of undetermined significance. (2012) (103)
- The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. (1999) (103)
- Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. (2009) (102)
- A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. (2017) (101)
- AL amyloidosis: from molecular mechanisms to targeted therapies. (2017) (101)
- The lung in amyloidosis (2017) (101)
- Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure (2012) (99)
- Rapid progression of familial amyloidotic polyneuropathy (2015) (94)
- Bortezomib in the treatment of AL amyloidosis: targeted therapy? (2007) (93)
- First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. (2004) (92)
- Saporin, a ribosome‐inactivating protein used to prepare immunotoxins, induces cell death via apoptosis (1996) (91)
- The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. (2012) (91)
- Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient (2019) (91)
- Amyloidosis in autoinflammatory syndromes. (2012) (91)
- International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) (2020) (89)
- Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. (2003) (89)
- Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide (2011) (89)
- Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis (2010) (89)
- The utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinic (2017) (89)
- Conformational Switching and Fibrillogenesis in the Amyloidogenic Fragment of Apolipoprotein A-I* (2003) (86)
- Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. (1986) (85)
- Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. (2015) (84)
- Amyloidosis and Waldenström's macroglobulinemia. (2004) (84)
- The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. (2008) (83)
- Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). (2004) (82)
- Gender-related risk of myocardial involvement in systemic amyloidosis (2008) (81)
- A modified high‐dose dexamethasone regimen for primary systemic (AL) amyloidosis (2001) (80)
- European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018) (80)
- Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. (2005) (79)
- Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy (2017) (78)
- Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. (2005) (78)
- The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. (2014) (78)
- Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin (1995) (78)
- Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis (2013) (76)
- Lysozyme: a paradigmatic molecule for the investigation of protein structure, function and misfolding. (2005) (75)
- Variable presentations of TTR‐related familial amyloid polyneuropathy in seventeen patients (2011) (74)
- Light chain amyloidosis: the heart of the problem (2013) (73)
- Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide (2009) (73)
- Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. (2020) (73)
- Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. (2002) (73)
- TREATMENT OF PRIMARY AMYLOIDOSIS (1978) (73)
- Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. (2004) (71)
- Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis (2016) (71)
- Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study (2020) (70)
- A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. (2017) (70)
- Amyloidosis: is a cure possible? (2008) (69)
- A novel AβPP mutation exclusively associated with cerebral amyloid angiopathy (2005) (68)
- Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. (2003) (68)
- LONG‐TERM EFFECTS OF PARENTERAL DICHLOROMETHYLENE BISPHOSPHONATE (CL2MBP) ON BONE DISEASE OF MYELOMA PATIENTS TREATED WITH CHEMOTHERAPY (1990) (67)
- Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity (1990) (66)
- A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis (2013) (66)
- Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay. (2010) (66)
- A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients. (2020) (65)
- Light and electron microscopy immunohistochemical characterization of amyloid deposits (1997) (65)
- The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. (2017) (64)
- New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. (1995) (64)
- Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. (2014) (64)
- The workings of the amyloid diseases (2007) (64)
- A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis (2014) (64)
- Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity? (2007) (62)
- β2‐Microglobulin isoforms display an heterogeneous affinity for type I collagen (2005) (62)
- Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance? (2005) (62)
- Impaired Osteoblastogenesis in a Murine Model of Dominant Osteogenesis Imperfecta: A New Target for Osteogenesis Imperfecta Pharmacological Therapy (2012) (61)
- A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL) (2002) (61)
- Systemic amyloidosis: novel therapies and role of biomarkers. (2016) (60)
- Light Chain Amyloidosis (2018) (60)
- Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). (2017) (58)
- Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. (2019) (58)
- BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. (2017) (57)
- Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis (2015) (57)
- Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. (2008) (57)
- 4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. (2000) (56)
- Evidence that amyloidogenic light chains undergo antigen-driven selection. (1998) (55)
- Biology and therapy of immunoglobulin deposition diseases. (1997) (54)
- N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma (2016) (54)
- Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. (1995) (54)
- Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity (2013) (54)
- Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. (2017) (54)
- Prognostic value of fragmented QRS in cardiac AL amyloidosis. (2013) (53)
- Autoantibody activity in Waldenstrom's macroglobulinemia. (2005) (53)
- Therapeutic advances demand accurate typing of amyloid deposits. (2001) (53)
- Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells (2017) (53)
- The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients (2011) (53)
- Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia (2016) (52)
- CyBorD: stellar response rates in AL amyloidosis. (2012) (52)
- European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. (2016) (52)
- The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. (1999) (52)
- Occurrence of monoclonal components in general practice: Clinical implications (1992) (52)
- Current treatment of AL amyloidosis (2009) (52)
- Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis (1998) (51)
- Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. (2011) (50)
- Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure (2001) (49)
- Study of three patients with monoclonal gammopathies and ‘lupus‐like’ anticoagulants (1989) (49)
- Guidelines for the Analysis of Bence Jones Protein (2003) (49)
- Acute phase proteins and prognosis in multiple myeloma (1993) (49)
- An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis (2014) (49)
- Clotting alterations in primary systemic amyloidosis. (2000) (49)
- Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM‐8 consensus panel (2017) (49)
- In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study (2016) (48)
- Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis (2005) (48)
- Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. (2006) (48)
- Haematological cancer: Redefining myeloma (2012) (47)
- Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open‐label trial (2017) (47)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. (2019) (47)
- Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". (2004) (47)
- Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. (2018) (46)
- TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients (2013) (46)
- Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study (2020) (45)
- Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients (2018) (45)
- Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. (2013) (45)
- A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. (2011) (44)
- First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) (2013) (44)
- Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. (1987) (44)
- Rare diseases and effective treatments: are we delivering? (2015) (44)
- Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis (2018) (43)
- Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? (2002) (43)
- AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. (2009) (43)
- Stabilization of amyloidogenic immunoglobulin light chains by small molecules (2019) (42)
- The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation. (2000) (42)
- Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis (2021) (41)
- ATTRv amyloidosis Italian Registry: clinical and epidemiological data (2020) (41)
- Reversal of nephrotic syndrome due to reactive amyloidosis (AA‐type) after excision of localized Castleman's disease (1994) (41)
- Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. (2018) (41)
- Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity (2017) (41)
- The clinical implications of monoclonal immunoglobulins. (1986) (41)
- The Diflunisal Trial: Study accrual and drug tolerance (2012) (40)
- Is accuracy of serum free light chain measurement achievable? (2016) (40)
- Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis (2013) (40)
- Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. (2006) (40)
- Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. (2011) (40)
- Therapy and management of systemic AL (primary) amyloidosis. (2006) (40)
- Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations (2021) (39)
- Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner (2020) (39)
- Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. (2001) (38)
- Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis (2007) (38)
- Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial (2017) (38)
- Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL) (2019) (38)
- The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway (2015) (37)
- Validation of the Criteria of Response to Treatment In AL Amyloidosis. (2010) (37)
- Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) (2006) (37)
- Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. (2017) (36)
- Multiple myeloma and related plasma cell dyscrasias. (1987) (36)
- Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays (2017) (35)
- Treatment of AL amyloidosis with 4'-lodo-4'-deoxydoxorubicin: an update. (1999) (35)
- Transplantation vs. conventional-dose therapy for amyloidosis (2011) (35)
- Proteomics of β2-microglobulin amyloid fibrils (2005) (35)
- The red cell distribution width (RDW): Value and role in preterm, IUGR (intrauterine growth restricted), full-term infants (2014) (34)
- Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial (2020) (34)
- Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. (1991) (34)
- Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. (2006) (33)
- MASS‐FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms (2018) (33)
- Mechanism of altered drug binding to serum proteins in pregnant women: studies with valproic acid. (1984) (33)
- Monitoring free light chains in serum using mass spectrometry (2016) (33)
- Systemic amyloidoses: what an internist should know. (2013) (33)
- Genetic microheterogeneity of human transthyretin detected by IEF (2007) (32)
- Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. (1995) (32)
- Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis (2012) (32)
- Novel strategies for the diagnosis and treatment of cardiac amyloidosis (2015) (32)
- Clinical proteomics for diagnosis and typing of systemic amyloidoses (2013) (32)
- Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021) (32)
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
- Serum prealbumin: an independent marker of short-term energy intake in the presence of multiple-organ disease involvement. (2013) (31)
- Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma (2017) (31)
- Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils. (1997) (31)
- Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. (2011) (31)
- A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. (2005) (31)
- New Drug Therapy of Amyloidoses: Resorption of AL-Type Deposits With (2016) (30)
- Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. (2012) (30)
- SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma (2012) (30)
- International uniform response criteria for multiple myeloma (2007) (30)
- Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis (2011) (30)
- Definition of Organ Involvement and Treatment Response in Primary Systemic Amyloidosis (AL): A Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis. (2004) (30)
- Therapies for cardiac light chain amyloidosis: An update. (2018) (29)
- Standardizing plasma protein measurements worldwide: a challenging enterprise (2010) (29)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. (2021) (28)
- Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. (2015) (28)
- A revised international prognostic score system for Waldenström’s macroglobulinemia (2019) (28)
- Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis (2007) (28)
- Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. (2003) (28)
- Attitudes about when and how to treat patients with AL amyloidosis: an international survey (2017) (28)
- Treatment of AL amyloidosis with bendamustine: a study of 122 patients. (2018) (28)
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis (2021) (27)
- Clinical Pregenetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry (2016) (27)
- Current concepts on the pathogenesis of systemic amyloidosis. (1996) (27)
- High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate (2020) (27)
- The diflunisal trial: update on study drug tolerance and disease progression (2011) (27)
- Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. (2012) (26)
- Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). (2008) (26)
- Lysine 58‐cleaved β2‐microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis‐related amyloidosis (2006) (26)
- Monoclonal IgM-related AL amyloidosis. (2016) (25)
- LEADING ARTICLE International uniform response criteria for multiple myeloma (2006) (25)
- Diagnostic Performance of Triggering Receptor Expressed on Myeloid Cells-1 and CD64 Index as Markers of Sepsis in Preterm Newborns (2013) (25)
- Mechanisms of renal damage in plasma cell dyscrasias: an overview. (2007) (25)
- ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. (2019) (25)
- Novel Therapies in Light Chain Amyloidosis (2017) (24)
- Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications. (1996) (24)
- Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis (2013) (24)
- Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response (2016) (24)
- The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease. (2011) (24)
- When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. (2019) (24)
- Immunoglobulin Light Chain Systemic Amyloidosis. (2016) (24)
- Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients (2019) (23)
- Infertility and hypergonadotropic hypogonadism as first evidence of hereditary apolipoprotein A-I amyloidosis. (2007) (23)
- Detection and identification of monoclonal components: immunoelectrophoresis on agarose gel and immunofixation on cellulose acetate compared. (1981) (23)
- How we treat Waldenström's macroglobulinemia. (2005) (23)
- A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia (1984) (23)
- A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis. (2009) (23)
- Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence. (1996) (23)
- A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis (2017) (22)
- AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. (1994) (22)
- Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions (2014) (22)
- Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. (2020) (22)
- A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis (2021) (22)
- Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients (2011) (22)
- Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits (2011) (22)
- Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions (2016) (22)
- Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. (2019) (22)
- International Prognostic Scoring System (IPSS) for Waldenström’s Macroglobulinemia (WM). (2006) (22)
- Treatment of painful bone lesions and hypercalcemia (1989) (21)
- Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis (2022) (21)
- Biochemical markers in early diagnosis and management of systemic amyloidoses (2014) (21)
- The Pavia Approach to Clinical Protein Analysis (2001) (21)
- Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. (2015) (21)
- Procalcitonin is not a reliable marker for the assessment of severity in acute pancreatitis without infectious complications. (2000) (21)
- MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study (2012) (21)
- Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL) (2014) (21)
- Amyloid and Related Disorders (2012) (20)
- Management of the elderly patient with AL amyloidosis. (2018) (20)
- Development and preparation of a new serum protein reference material: feasibility studies and processing (2010) (20)
- Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. (1999) (20)
- A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli (2013) (20)
- Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis (2014) (20)
- Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis (2017) (20)
- Pathogenesis of Renal Failure in Multiple Myeloma: Any Role of Contrast Media? (2014) (20)
- Amyloidosis and Ocular Involvement: an Overview (2019) (20)
- Analysis of Hepatitis C Virus Hypervariable Region 1 Sequence from Cryoglobulinemic Patients and Associated Controls (2007) (19)
- nAddendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. (2021) (19)
- Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. (2004) (19)
- Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis (2019) (19)
- A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis (2020) (19)
- Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide. (2012) (19)
- Complete remission in plasma cell leukaemia (1986) (19)
- Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy (2020) (19)
- Biological features of the clone involved in primary amyloidosis (AL) (2001) (19)
- Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging (2021) (18)
- Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1‐associated periodic syndrome (2016) (18)
- Proteomics of beta2-microglobulin amyloid fibrils. (2005) (18)
- Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis (2020) (18)
- Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis (2021) (18)
- Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment. (2014) (18)
- Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis (1999) (18)
- Utility of biochemical markers in the follow-up of heart transplant recipients. (2003) (18)
- Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. (2020) (18)
- Monoclonal autoimmunity in hematology. (1991) (18)
- A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma. (1994) (17)
- Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer (2019) (17)
- Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients (2018) (17)
- Heavy chain disease can be detected by capillary zone electrophoresis. (2005) (17)
- Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. (1984) (17)
- Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the κ light chain locus in λ myeloma (2004) (17)
- Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis (2019) (17)
- Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations (2011) (17)
- Inherent biophysical properties modulate the toxicity of soluble amyloidogenic light chains. (2019) (16)
- Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network (2020) (16)
- New concepts in the treatment and diagnosis of amyloidosis (2018) (16)
- Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses (2020) (16)
- Neuropathies associated with monoclonal gammapathies. (1995) (16)
- Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. (2019) (16)
- Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years (2020) (15)
- Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment. (1996) (15)
- Early identification of transthyretin-related hereditary cardiac amyloidosis. (2014) (15)
- The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis (2016) (15)
- Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee (2022) (15)
- Protease‐sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation (2021) (15)
- Predicting survival in light chain amyloidosis (2019) (15)
- Pancreatic involvement during the early phase of shock. (2002) (15)
- Serum Thymidine Kinase and Beta-2 Microglobulin in Monoclonal Gammopathies (1987) (14)
- Membrane CD22 defines circulating myeloma-related cells as mature or later B cells. (1997) (14)
- Electrophoresis: cellulose acetate vs agarose gel, visual inspection vs densitometry. (1981) (14)
- Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system (2017) (14)
- Systemic amyloidoses and proteomics: The state of the art (2016) (14)
- Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient (2018) (14)
- Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. (1998) (14)
- A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis (2010) (13)
- Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. (2011) (13)
- Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy (2020) (13)
- Risk stratification in Waldenström macroglobulinemia (2012) (13)
- How I Treat AL Amyloidosis. (2021) (13)
- Liver Transplantation: An Effective Treatment For Familial ATTR Amyloidosis (2002) (13)
- Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic (2020) (13)
- Hereditary amyloidosis [2] (multiple letters) (2002) (13)
- Management of AL amyloidosis in 2020. (2020) (13)
- High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy (2013) (13)
- Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio. (1985) (12)
- Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda. (2018) (12)
- Diagnostic challenges of amyloidosis in Waldenström macroglobulinemia. (2013) (12)
- Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis (2016) (12)
- Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. (1986) (12)
- Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. (2011) (12)
- European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease (2011) (12)
- The elusive pathogenesis of Schnitzler syndrome. (2018) (12)
- The second riboflavin-binding myeloma IgGλDOT I. Biochemical and functional characterization (1990) (12)
- Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance (2019) (12)
- Paraprotein interference in an assay of conjugated bilirubin. (2005) (12)
- Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis (2008) (12)
- Treatment of AL Amyloidosis with Bendamustine (2012) (11)
- Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel ‘hot spot’ in codon 47 (2000) (11)
- Differential transplacental binding of valproic acid: influence of free fatty acids. (1984) (11)
- Waldenström macroglobulinemia. (2018) (11)
- Serum-free light chain analysis: works in progress (2009) (11)
- Non-lymphoplasmacytic lymphomas underlying light chain amyloidosis: distinct clinical features and outcome. (2019) (11)
- Metrological sharp shooting for plasma proteins and peptides: The need for reference materials for accurate measurements in clinical proteomics and in vitro diagnostics to generate reliable results (2007) (11)
- Use of the Novel Monoclonal Assay for the Measurement of Circulating Free Light Chain in the Diagnosis, Prognostication of Survival and Assessment of Response to Therapy in AL Amyloidosis (2012) (11)
- Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations (2011) (11)
- Beta2-microglobulin causes abnormal phosphatidylserine exposure in human red blood cells. (2011) (11)
- Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis (2020) (11)
- Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL) (2007) (11)
- Structural characterization of κ II Inc, a new amyloid immunoglobulin (1989) (10)
- First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network (2020) (10)
- Systemic amyloidosis: are we moving ahead? (2004) (10)
- Introducing the New Editor of Amyloid: the Journal of Protein Folding Disorders, Per Westermark, M.D., Ph.D. (2010) (10)
- Determining the significance of MGUS. (2014) (10)
- Immune mechanisms of AL amyloidosis (2004) (10)
- Use of an Anti‐Idiotypic Monoclonal Antibody in Studying Amyloidogenic Light Chains in Cells, Urine and Fibrils: Pathophysiology and Clinical Implications (1992) (10)
- PLASMA CELL LEUKEMIA : Consensus Statement on Diagnostic Requirements , Response Criteria , and Treatment Recommendations by the International Myeloma Working Group ( IMWG ) (2014) (10)
- Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. (2021) (9)
- Measurement of free light chains in urine. (2001) (9)
- Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022) (9)
- Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis (2008) (9)
- Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (9)
- The Merlini, Waldenström, Jayakar staging system revisited (1989) (9)
- Pharmacokinetics of peptichemio in myeloma patients: release ofm-l-sarcolysin in vivo and in vitro (2004) (9)
- Characterization for anti-cytoplasmic antibodies specificity by morphological and molecular techniques (2012) (9)
- A patient with AL amyloidosis with negative free light chain results (2016) (9)
- Peptichemio, Vincristine, Prednisone Induction Treatment in Multiple Myeloma (1985) (9)
- Proteomics in protein misfolding diseases (2009) (9)
- Immunochemical characterization of the cryoglobulins: pathophysiologic implications. (1995) (9)
- Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis (2017) (9)
- Characterization of the two unique human anti-flavin monoclonal immunoglobulins. (1995) (8)
- Enlightening light chain deposition disease. (2015) (8)
- Amino acid sequence of the FV region of a human monoclonal IgM (NOV) with specificity for the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1, which cross-reacts with polynucleotides and with denatured DNA. (1991) (8)
- Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis (2017) (8)
- Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney. (2016) (8)
- Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) (2021) (8)
- Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study (2020) (8)
- Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis (2021) (8)
- Assessing Proteostasis and Proteasome Stress In Light Chain Amyloidosis (2010) (8)
- Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients, (2011) (8)
- Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma (2013) (8)
- Familial AL-amyloidosis in three Italian siblings. (1996) (8)
- A SIMPLE VOLTAGE/MASS INDEX IMPROVES DIAGNOSIS OF CARDIAC AMYLOIDOSIS: AN ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC STUDY OF 570 PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY (2012) (8)
- Treating advanced cardiac damage in light chain amyloidosis: still an unmet need (2014) (8)
- S875 SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN-IN RESULTS OF ANDROMEDA (2019) (8)
- A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options (2019) (8)
- Comparison of three strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. (2005) (8)
- Hepatitis B virus markers in monoclonal (type I and II) and polyclonal (type III) cryoglobulinemias. (1988) (8)
- Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis (2012) (7)
- Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case Study (2011) (7)
- Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS (2021) (7)
- Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy (2021) (7)
- More on immunofixation vs immunoelectrophoresis. (1984) (7)
- Peptichemio induction therapy in myelomatosis (2004) (7)
- The laboratory investigation of monoclonal components. (1988) (7)
- Treatment with Oral Melphalan and Dexamethasone of An Extended Patient Population with AL Amyloidosis. (2009) (7)
- Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts (2017) (7)
- Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis (2012) (7)
- Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network (2009) (7)
- [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know]. (2002) (7)
- Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans (2014) (7)
- THU0376 Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) (2012) (7)
- A plea to overcome the concept of “staging” and related inadequacy in multiple myeloma (1991) (7)
- Proliferative activity, response to therapy and survival in multiple myeloma. (1984) (7)
- Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster. (2009) (7)
- High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors (2013) (7)
- Selective bone marrow involvement of lymphoplasmacytic cells secreting monoclonal IgA rheumatoid factor in a patient with Sjögren's syndrome and serum hyperviscosity. (1987) (7)
- An IgM monoclonal protein with multiple serological specificities. (1979) (7)
- Nodular macroglossia with combined light chain and beta-2 microglobulin deposition in a long-term dialysis patient. (2001) (7)
- Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. (1996) (7)
- Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial. (2020) (7)
- Vincristine in the treatment of multiple myeloma. (1980) (7)
- Advances in proteomic study of cardiac amyloidosis: progress and potential (2016) (7)
- Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). (2008) (7)
- Prognostication of survival and progression to dialysis in AA amyloidosis (2017) (7)
- Etiology of amyloidosis determines myocardial 99mTc-DPD uptake in amyloidotic cardiomyopathy. (2015) (7)
- Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium (2015) (7)
- Protein Aggregation (2001) (6)
- Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis (2009) (6)
- Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. (2006) (6)
- Immunochemical characteristics of a particular cryoglobulin. A new cryoglobulin subgroup? (1991) (6)
- Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients (2015) (6)
- Transthyretin, nutrition, and inflammation: Response to Dr. Bernstein [6] (2007) (6)
- [Amyloidosis AL]. (1989) (6)
- Molecular imaging of misfolded protein pathology for early clues to involvement of the heart (2014) (6)
- Age-related amyloidosis outside the brain: A state-of-the-art review (2021) (6)
- Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing (2018) (6)
- What does minimal residual disease mean in AL amyloidosis? (2018) (6)
- Utility of bisphosphonates in treating bone metastases (1996) (6)
- Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda (2020) (6)
- Conformational dynamics of the β2-microglobulin C terminal in the cell-membrane-anchored major histocompatibility complex type I (2000) (6)
- Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis (2017) (5)
- OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis (2019) (5)
- Definition of organ involvement and treatment response in primary systemic amyloidosis (AL) (2004) (5)
- Embryonic stem and haematopoietic progenitor cells resist to Aβ oligomer toxicity and maintain the differentiation potency in culture (2010) (5)
- Alpha heavy chain disease: report of two cases. (1985) (5)
- Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study. (2019) (5)
- Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients (2021) (5)
- Imaging of Systemic Amyloidosis (2010) (5)
- Indicaciones clínicas para los ensayos deproteínas plasmáticas: transtiretina(prealbúmina) en inflamación ydesnutrición (2008) (5)
- Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis (2020) (5)
- Amyloid Typing: Immunoelectron Microscopy (2012) (5)
- Autologous Stem Cell and Kidney Transplantation for Primary Amyloidosis Associated with ESRD: Which Should Come First? (2005) (5)
- Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies (2016) (5)
- Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis (2011) (5)
- Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice. (2019) (5)
- Abstract 16852: A Simple Voltage/Mass Index Improves Diagnosis of Cardiac Amyloidosis in Patients With Unexplained Left Ventricular “Hypertrophy”: An Electrocardiographic and Echocardiographic Study of More Than 500 Patients (2010) (5)
- Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group (2022) (5)
- Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome (2017) (5)
- Fair Pricing of Innovative Medicines: An EHA Position Paper (2020) (5)
- Access to Affordable Orphan Medicines in Europe: An EHA Position Paper (2020) (5)
- Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis (2016) (5)
- Correction to: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging (2021) (5)
- Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network (2021) (5)
- Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside (2020) (5)
- Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma. (2004) (5)
- Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case–control study (2015) (4)
- Late-onset familial Mediterranean fever: an atypical presentation of dermatologic interest. (2007) (4)
- Agarose gel electrophoresis in newborns. (1981) (4)
- Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda (2020) (4)
- Monoclonal gammapathies. (1997) (4)
- Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome (2018) (4)
- P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK (2021) (4)
- A Proteomic Approach to the Study of Systemic Amyloidoses (2007) (4)
- Graded Renal Response Criteria for Light Chain (AL) Amyloidosis (2021) (4)
- Functional study of autonomic neuropathy in primary (AL) amyloidosis (1996) (4)
- Cardiac light-chain deposition disease relapsing in the transplanted heart (2017) (4)
- Serum markers of myocardial damage in acute pancreatitis: a prospective time course study. (2015) (4)
- Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis (2021) (4)
- Clinical Trial for Ttr Amyloidosis Using Diflunisal (2007) (4)
- How do we improve treatments for patients with amyloidosis using proteomics? (2017) (4)
- The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction (2016) (4)
- Regulated expression of amyloidogenic immunoglobulin light chains in mice (2017) (4)
- A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results (2019) (4)
- Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival (2021) (4)
- An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis (2022) (4)
- Search for AL amyloidosis risk factors using Mendelian randomization. (2021) (4)
- Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival. (2022) (4)
- Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients (2022) (4)
- Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis (2022) (4)
- Misdiagnoses of transthyretin amyloidosis: a clinical and electrodiagnostic study (2015) (4)
- Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected? (2018) (3)
- SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (2019) (3)
- Identification of Specific Plasma Proteins Determining the Agarose Gel Electrophoresis by the Immunosubtraction Technique (1983) (3)
- Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis. (2020) (3)
- Patterns of Relapse after Upfront Therapy in AL Amyloidosis (2016) (3)
- THE CONTRIBUTION OF THE EKG / ECHOCARDIOGRAPHIC MASS RATIO TO THE DIAGNOSIS OF CARDIAC AL AMYLOIDOSIS IN UNEXPLAINED LV HYPERTROPHY: 4C.05 (2010) (3)
- The Clinical Impact of Proteomics in Amyloid Typing. (2021) (3)
- Bone marrow amyloidosis. (2006) (3)
- N-terminal fragment of brain natriuretic peptide (NT-ProBNP) - a new response criterion in AL amyloidosis (2010) (3)
- Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. (2020) (3)
- Single‐molecule real‐time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies (2022) (3)
- A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis (2021) (3)
- Correction: First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) (2013) (3)
- Gene expression of pyrogenic cytokines in Hodgkin's disease lymph nodes. (1992) (3)
- International prognostic scoring system for Waldenström s Macroglobulinemia Short title: Prognostic index for Waldenström Macroglobulinemia (2017) (3)
- Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. (2019) (3)
- OP038 NUTRITIONAL STATUS AND QUALITY OF LIFE IN OUTPATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS (AL) AT DIAGNOSIS (2010) (3)
- Recommendations for appropriate serum electrophoresis requests: the Italian approach (2013) (3)
- Imaging of Myocardial Amyloid Involvement with 99m — Tc Aprotinin (1997) (3)
- Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study (2021) (3)
- Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations (2019) (3)
- Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma. (2008) (3)
- Multiple myeloma. (1990) (3)
- Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres (2021) (3)
- Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324) (2018) (2)
- Here to Stay: Biosimilars in Hematology (2019) (2)
- [Taste changes in patients with AL amyloidosis. Preliminary studies]. (1994) (2)
- Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study. (2010) (2)
- The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. (2015) (2)
- Use of Various Electroimmune Techniques in the Diagnosis and Follow-Up of Patients with AL Amyloidosis (1988) (2)
- SERUM PROTEIN ANALYSIS BY MOLECULAR INTERPRETATION OF CELLULOSE ACETATE ELECTROPHORESIS: EVALUATION OF ITS CLINICAL USEFULNESS (1980) (2)
- Reducing the amyloid burden through immunotherapy: a major therapeutic advance. (2011) (2)
- Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response (2017) (2)
- An ECG/ECHO comparison between AL and ATTR cardiac amyloidosis at diagnosis (2013) (2)
- Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update (2022) (2)
- Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders (2021) (2)
- TNFRSF1A Mutations in Italian Patients Affected by Apparently Sporadic Periodic Fever Syndrome (2004) (2)
- Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis (2022) (2)
- Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis (2012) (2)
- OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study (2021) (2)
- Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial (2018) (2)
- Future Perspectives (2020) (2)
- Late onset cardiomyopathy due to transthyretin Ile68Leu mutation: a cardiogenic variant of familial amyloidosis potentially mimicking sarcomeric hypertrophic cardiomyopathy (2013) (2)
- Pilot Study with Lenalidomide in Patients with POEMS Syndrome (2011) (2)
- Persistence of Minimal Residual Disease by Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients With AL Amyloidosis (2017) (2)
- Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis (2017) (2)
- Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome (2013) (2)
- Serum Alpha-1-Acid-Glycoprotein, Haptoglobin and C3 in Hodgkin’s Disease (1982) (2)
- 3 year follow-up results on a treatment for amyloid A (AA) amyloidosis: Efficacy and safety of eprodisate (NC-503; 1,3-propanedisulfonate), the first of a new class of anti-amyloid compounds. (2006) (2)
- Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis (2018) (2)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. (2021) (2)
- Patterns of relapse after upfront bortezomib therapy in AL amyloidosis (2017) (2)
- In search of the most effective therapy for light chain amyloidosis (2021) (2)
- Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update (2022) (2)
- Abstract 2693: Mass spectrometric approach to identify N-glycosylation of light chain in patients with immunoglobulin light chain amyloidosis (AL) (2018) (2)
- Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium (2015) (2)
- Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis (2022) (2)
- PP100-SUN: Nutritional Counseling in Systemic Immunoglobulin Light-Chain (AL) Amyloidosis: A Prospective Randomized, Controlled Trial (2014) (2)
- Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis. (2013) (2)
- PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA (2019) (2)
- The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis (2019) (2)
- Structural characterization of kappa II Inc, a new amyloid immunoglobulin. (1989) (2)
- Hereditary amyloidosis. (2002) (2)
- Efficacy of peptide bound m-l-sarcolysin (peptichemio) on melphalan resistant human myeloma cellsIn vitro (1991) (2)
- Systemic Amyloidosis and Monoclonal Gammopathy in Three Italian Siblings : A Familian Case of AL-Amyloidosis? (1991) (2)
- Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study (2022) (2)
- FISH reveals chromosomal abnormalities in 41 Patients with Systemic Amyloidosis (AL). (2010) (2)
- The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy (2019) (2)
- Molecular Heterogeneity and γ-Carboxyglutamic Acid Content of Bence-Jones Proteins: Possible Relevance to Amyloidogenicity (1986) (2)
- Indicaciones clínicas para los ensayos de proteínas plasmáticas: transtiretina (prealbúmina) en inflamación y (2008) (2)
- An interleukin 2 binding factor in human serum. (1988) (1)
- Immunoglobulin Light Chain (2014) (1)
- Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial (2018) (1)
- Beneficial effect of eprodisate (NC-503) on the preservation of kidney function in AA amyloidosis patients : 3-year follow-up results (2007) (1)
- Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis (2019) (1)
- Sharpening therapeutic strategy in AL amyloidosis (2004) (1)
- Chapter 87 – Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (2008) (1)
- P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK (2022) (1)
- PS1221 LONG-TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO-TTR OPEN-LABEL EXTENSION 2-YEAR UPDATE (2019) (1)
- A simple electrophoretic procedure for isoamylase separation (1984) (1)
- patients with relapsed systemic AL amyloidosis : results of a phase 1 / 2 Efficacy and safety of once-weekly and twice-weekly bortezomib (2011) (1)
- OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival (2021) (1)
- Can ISSWM be used for making treatment decisions? (2011) (1)
- First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant (2013) (1)
- EFFECT OF DARATUMUMAB, BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE ON CARDIAC FUNCTION AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED AL AMYLOIDOSIS WITH CARDIAC INVOLVEMENT: RESULTS FROM THE PHASE 3 ANDROMEDA STUDY (2021) (1)
- analysis of 123 treated patients A new improved clinical staging system for multiple myeloma based on (2011) (1)
- macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström (2014) (1)
- Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial (2018) (1)
- The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis (2020) (1)
- High sensitivity M‐protein detection in a case of light‐chain cardiac amyloidosis without evidence of plasma cell dyscrasia (2019) (1)
- Neurological Data Collection Protocol On Tafamidis Meglumine Treatment For Familial Amyloid Polyneuropathy: Preliminary Data On Patients Enrolled By The Italian Network (2013) (1)
- Alpha-2-HS-glycoprotein in multiple myeloma. (1982) (1)
- A 99mTc-Labeled Synthetic Cyclic Peptide (Aprotinin Analogue) with High Affinity for Amyloid Fibrils (2011) (1)
- Application of monoclonal anti-idiotypes in the study of AL amyloidosis: therapeutic implications. (1993) (1)
- Glycosylation of Immunoglobulin Light Chains is Associated with Amyloidosis (2017) (1)
- Future Developments in Light Chain Amyloidosis Management. (2022) (1)
- Treatment for amyloid A (AA) amyloidosis with eprodisate disodium (NC-503): 2-year results of efficacy and safety from a multi-center international trial (2006) (1)
- Reply to S. Girnius et al. (2013) (1)
- Multivariate statistical analysis of quantitative serum protein data in populations of Rwanda. (1981) (1)
- Beta-2-Microglobulin Does Not Deposit in Abdominal Fat Tissue of Long-Term Hemodialysis Patients (1991) (1)
- Inotersen Improves Quality of Life and Neuropathy in Patients with Hereditary Transthyretin (HATTR) Amyloidosis with Polyneuropathy: Results of the Phase 3 Study Neuro-TTR (2018) (1)
- Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity (2017) (1)
- Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years (2016) (1)
- Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis (2019) (1)
- Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group (2022) (1)
- Pathogenesis of Systemic Amyloidoses (2010) (1)
- Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study (2019) (1)
- Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins. (2008) (1)
- A focus on recent advances in proteomics – one step closer to entrance into the clinical arena (2009) (1)
- amyloidosis: results of a phase 1 dose-escalation study Weekly and twice-weekly bortezomib in patients with systemic AL (2009) (1)
- Burden of Hereditary Transthyretin Amyloidosis With Polyneuropathy in Patients Enrolled in the Phase 3 Study NEURO-TTR (P1.331) (2018) (1)
- Treatment of AA amyloidosis: Results of a multi-center, randomized, placebo-controlled trial with 1,3-propanedisulfonate (1,3-PDS; NC-503). (2005) (1)
- Immunoenzymatic detection of proteins transferred on nitrocellulose after fixation and staining in polyacrylamide gel. (1988) (1)
- Neuropathies associated with monoclonal gammapathies. (1994) (1)
- Plasma proteins modifications in pre-term newborns. (1981) (1)
- MYOCARDIAL SYSTOLIC DYSFUNCTION IN CARDIAC AL AMYLOIDOSIS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION: P2.73 (2004) (1)
- AA-amyloidosis in cats (Felis catus) housed in shelters (2022) (1)
- Symposium on Amyloid Cardiomyopathy: Diagnosis and Treatment, Pavia, September 21, 1996 (1997) (1)
- Experience with a Patient-Adapted Approach to Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis (2004) (1)
- Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib (2010) (1)
- Kidney Involvement in Light Chain Amyloidosis (2017) (1)
- AMICA: an electronic patient record specifically designed for an amyloidosis network (2011) (1)
- Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey (2020) (1)
- Treatment of multiple myeloma with vincristine. (1980) (1)
- Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter (2022) (1)
- Treatment of primary amyloidosis. (1995) (1)
- High Molecular Weight Proteins, Sensitive to Collagenase Digestion are Intimate Constituents of Amyloid Deposits (1991) (1)
- AnIgMmonoclonal protein withmultiple serological specificities (1979) (1)
- Anatomic and Clinical Clues to In Vivo Mechanisms of Amyloidogenesis (2008) (1)
- Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN) (2019) (1)
- 5234D flow CMR for diastolic function assessment in cardiac amyloidosis (2019) (1)
- remissions in AL amyloidosis Treatment with oral melphalan plus dexamethasone produces long-term (2011) (1)
- Identification Of Reversible Organ Damage and Of Early Markers Of Response To Treatment In Renal AL Amyloidosis: A Study On 461 Patients (2013) (1)
- Scintigraphic imaging and turnover studies with (131) I-serum amyloid P component (SAP) in systemic amyloidosis (1999) (1)
- Waldenström’s disease (2004) (1)
- Aprotinin 99mTc Myocardial Scan: Risk Stratification of Cardiac Events in Patients with Al/Attr Amyloidosis (1999) (1)
- A powerful oral triplet for AL amyloidosis (2020) (1)
- Organ Survival in AL Amyloidosis with Renal Involvement (2004) (1)
- Phase 3 study of the oral proteasome inhibitor ixazomib for relapsed/refractory AL amyloidosis: TOURMALINE-AL1 (2015) (1)
- MYOCARDIAL CONTRACTION FRACTION, A NEW ECHOCARDIOGRAPHIC PARAMETER FOR PREDICTION OF SURVIVAL IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS (2016) (1)
- A sulfhydryl-rich IgM protein with multiple serological specificities. (1987) (1)
- Serum IgD in Hodgkin's disease. (1981) (1)
- Transthyretin-associated Familial Amyloid Polyneuropathy – Current and Emerging Therapies (2012) (1)
- Hereditary apolipoprotein A1 amyloidosis with cutaneous and cardiac involvement: a long familial history (2014) (1)
- Abstract 13149: Survival Benefit With Higher Dose Tafamidis in Patients With Hereditary and Wild-type Transthyretin Amyloid Cardiomyopathy (2020) (1)
- Bases of sensitivity of light chain amyloidosis to proteasome inhibitors: assessing proteostasis and proteasome stress (2011) (0)
- Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 2-Year Update (S27.008) (2019) (0)
- PReS-FINAL-1010: circulating micrornas in traps (2013) (0)
- Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells (2017) (0)
- ASO-PCR for clonal light chains reveals common tumor peripheral blood involvement and apheretic stem cell harvest contamination in AL amyloidosis (1998) (0)
- Highlights Neuro Sci Vol 34 Num 7 July 2013 (2013) (0)
- Treatment of neoplastic bone destruction with bisphosphonates (1997) (0)
- Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib‐dexamethasone versus physician's choice (2023) (0)
- 1H assignments of W60G mutant of human beta2-microglobulin (2007) (0)
- Rate of M-component changes and clinical course of 23 responsive myeloma patients. (1984) (0)
- Robert Kisilevsky, MD, PhD, 1937-2019. (2019) (0)
- Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. (2023) (0)
- [Use of diphosphonates in the treatment of hypercalcemia in multiple myeloma: efficacy of 4-amino-hydroxybutylidene-1,1-bisphosphonate (AHButBP)]. (1988) (0)
- [Combined treatment, polychemotherapy and amino-hydroxybutylidene-diphosphonate, of a patient with multiple myeloma: remission and long survival]. (1988) (0)
- International Society of Amyloidosis (2010) (0)
- European Society of Cardiology Working Group on Myocardial & Pericardial Diseases - Issue 19 - December 09 (2010) (0)
- Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy (2022) (0)
- A case of IgM(kappa) monoclonal gammopathy simulating an IgM-IgG biclonal gammopathy. (1990) (0)
- Preferential vx germline gene usage in primary amyloidosis (2000) (0)
- Nutritional Status of Outpatients with Al Systemic Amyloidosis (2004) (0)
- Solution structure of W60G mutant of human beta2-microglobulin (2007) (0)
- Introduction (2020) (0)
- A418 AL Amyloidosis with IgM Monoclonal Protein (2009) (0)
- Editorial Amyloid fibril protein (2002) (0)
- 593 PRESENTATION AND OUTCOME OF PATIENTS WITH COEXISTING CARDIAC AL AND ATTR AMYLOIDOSIS (2022) (0)
- 'Standing on the Shoulders of the Giants': Dr. Giampaolo Merlini. (2023) (0)
- MP078MORPHO-FUNCTIONAL CORRELATIONS IN RENAL AMYLOIDOSIS (2016) (0)
- Sustained effects of exercise training on plasma NT-proBNP levels in patients with stable heart failure (2005) (0)
- Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy (2017) (0)
- Refining therapy for AL amyloidosis (2006) (0)
- A Case of IgM(κ) Monoclonal Gammopathy Simulating an IgM-IgG Biclonal Gammopathy (1990) (0)
- A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets (2023) (0)
- Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis. (2006) (0)
- Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis (2021) (0)
- Serum free light chain analysis in the diagnosis and management of multiple myeloma and related (2014) (0)
- Immunoassay methods for determination of serum C-reactive protein levels (1984) (0)
- Exciting new agents in multiple myeloma (2006) (0)
- Light Chains With Heavy Effects. (2020) (0)
- Treatment of Multiple Myeloma and Related Disorders: WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA (2008) (0)
- Paraprotein interference in the Olympus conjugated bilirubin assay (2005) (0)
- Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area (2015) (0)
- Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome (2014) (0)
- Significant delay in the progression to dialysis/ESIRD for AA amyloidosis patients treated with eprodisate (NC-503) : 3 years of follow-up (2007) (0)
- Primary Structure of A V K II Light Chain from a Patient with Amyloid Arthropathy (1988) (0)
- [AL amyloidosis]. (2016) (0)
- Unusual Manifestations of IgM Monoclonal Gammopathies (2017) (0)
- Carbohydrate-deficient transferrin (CDT): Analytical and interpretative strategies (2010) (0)
- Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis (2007) (0)
- Cardiac transthyretin wild-type amyloidosis (ATTRwt): a prospective study of 400 patients followed at the Italian referral center (2020) (0)
- Selection Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven (2013) (0)
- Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). (2019) (0)
- Impact of fibrillex, an anti-amyloid product, on amyloid A (AA) protein content in abdominal fat tissue biopsies from patients with AA amyloidosis : Results from a pivotal international trial (2005) (0)
- MONOCLONAL GAMMOPATHIES OF DETERMINED SIGNIFICANCE Management of AL amyloidosis in 2020 (2020) (0)
- Bence Jones Proteinemia Without Bence Jones Proteinuria in AL Amyloidosis (1991) (0)
- The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center (2015) (0)
- Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab (2018) (0)
- IX International Symposium on Amyloidosis July 15–21, 2001 Budapest, Hungary (2002) (0)
- PP060-MON MALNUTRITION AT DIAGNOSIS INDEPENDENTLY PREDICTS MORTALITY IN PATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS (AL) (2012) (0)
- OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis (2021) (0)
- JCO.2015.63.6530.full (2016) (0)
- Primary Systemic Amyloidosis (2018) (0)
- (AL) is an effective but toxic treatment for patients with primary amyloidosis The combination of thalidomide and intermediate-dose dexamethasone (2013) (0)
- Subject Index, Vol. 67, 1982 (2004) (0)
- A New Method of Response Assessment in AL Amyloidosis Using NT-ProBNP with Hematologic Response (2009) (0)
- Left Ventricular Systolic Function in Patients with Cardiac Al Amyloidosis (2007) (0)
- Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis. (2023) (0)
- The Natural History of Hereditary Apolipoprotein a-I Amyloidosis according to a Large Series of Italian Leu75pro Patients (2007) (0)
- The Reduction of the Serum Concentration of the Amyloidogenic Light-Chain in Cardiac AL Results in Prompt Improvement of Myocardial Function and Prolonged Survival Despite Unalterd Amount of Myocardial Amyloid Deposits (2004) (0)
- Amyloid-Induced Myocardial Dysfunction Depends on Biochemical Characteristics of the Amyloidogenic Protein (2004) (0)
- Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma (2021) (0)
- New tools to diagnose and follow FAC patients: biomarkers (2015) (0)
- Chapter 2 Imaging of Systemic Amyloidosis (2012) (0)
- The role of gender and age in cardiac AL amyloidosis (2013) (0)
- Is a restrictive LV filling pattern invariably present in restrictive cardiomyopathy? The case of cardiac AL amyloidosis (2013) (0)
- Disphosphonates to treat multiple myeloma associated hypercalcaemia: Effect of aminohydroxybutylidene-disphosphonate (AHBuDP) (1988) (0)
- Italy FluoresceinEffecton Magnesium andTotal ProteinDeterminations (2004) (0)
- Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant. (2023) (0)
- Redirecting proteoxicity (2020) (0)
- Combined therapy (aminohydroxybutilidene-disphosphonate chemotherapy) to treat multiple myeloma: Complete remission and long survival (1988) (0)
- N-terminal pro natriuretic peptide type B ( NT-proBNP) is a reliable marker of cardiac response in patients with AL amyloidosis and renal failure (2010) (0)
- Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial (2021) (0)
- Symposium on Amyloid Cardiomyopathy : Diagnosis and (1997) (0)
- 591 SEQUENCE OF DIAGNOSTIC TESTING IN CARDIAC AMYLOIDOSIS: EARLY MONOCLONAL PROTEIN STUDY IS ASSOCIATED WITH BETTER OUTCOMES IN AL AMYLOIDOSIS (2022) (0)
- A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis (2014) (0)
- The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction. (2016) (0)
- Two-hit strategy for treating AL amyloidosis? (2021) (0)
- Characterization for anti-cytoplasmic antibodies specificity by morphological and molecular techniques (2012) (0)
- Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. (2023) (0)
- CLINICAL TRIALS OBSERVATIONS BDR in newly diagnosed patients with WM: fi nal analysis of a phase 2 study after a minimum follow-up of 6 years (2017) (0)
- Abstract 18695: Role of Autophagy in Amyloidogenic Light Chain Induced Cardiac Toxicity (2012) (0)
- A Novel Mutation (Ser59Pro) in the TNFRSF1A Gene Associated with Adult- Onset Sporadic Traps (2012) (0)
- improvement of survival in AL amyloidosis natriuretic peptide type B decrease simultaneously in association with Circulating amyloidogenic free light chains and serum N-terminal (2012) (0)
- University of Southern Denmark Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
- Pavia, Italy Symposium. Recent Developments in Amyloidosis, June 1, 1995 (1996) (0)
- Robert Kisilevsky, MD, PhD, 1937–2019 (2019) (0)
- The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018 (2023) (0)
- A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis (2020) (0)
- Micropolyspora faeni antigens of three commercial extracts (1984) (0)
- Anti-Casein Antibodies in the Serum of Patients with Al Amyloidosis (1988) (0)
- Amyloid Versus Non-Amyloid Immunoglobulin Deposits (2004) (0)
- PP131-MON SERUM PREALBUMIN: AN INDEPENDENT MARKER OF SHORT-TERM ENERGY INTAKE (2012) (0)
- Effects of Patisiran, an RNA Interference Therapeutic, on Regional Left Ventricular Myocardial Deformation in Hereditary Transthyretin Amyloidosis: The APOLLO Study (2019) (0)
- Effects of Patisiran, an RNA Interference Therapeutic, on Regional Left Ventricular Myocardial Deformation in Hereditary Transthyretin Amyloidosis: The APOLLO Study (2019) (0)
- Safety and Efficacy of Inotersen in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTR) (N2.001) (2018) (0)
- OR10-004 - Circulating micrornas in TRAPS (2013) (0)
- A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM) (2015) (0)
- Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis (2017) (0)
- In situ study of protein aggregates by FTIR spectroscopy coupled to multivariate analysis (2019) (0)
- Amyloid fibrils with fragmented ATTR may be the rule in non-Val30Met ATTR amyloidosis (2011) (0)
- Response observed during treatment for amyloid a (AA) amyloidosis with eprodisate (NC-503; 1,3-propanedisulfonate) after 2 years in patients with familial mediterranean fever in comparison to patients with rheumatoid arthritis. (2006) (0)
- Lymphoma: Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma (2013) (0)
- Critical considerations on a comparative study of two staging systems for multiple myeloma. (1984) (0)
- The Role of Immuno-Electron Microscopy in Amyloid Typing: The Experience of the Pavia Referral Center (2015) (0)
- Syddansk Universitet Diagnosis , treatment , and response assessment in solitary plasmacytoma updated recommendations from a European Expert (2018) (0)
- Paraprotein interferences in the Olympus conjugated bilirubun assay (2005) (0)
- Inotersen Improves Norfolk Quality of Life-Diabetic Neuropathy Measures in Patients With Hereditary Transthyretin Amyloidosis with Polyneuropathy in the Phase 3 Study NEURO-TTR (S5.006) (2018) (0)
- Evaluation of different markers to predict ventilator associated pneumonia severity in brain injured patients (2004) (0)
- amyloid-associated germline gene segment III) as a new λ amyloidosis and normal bone marrow identifies 3r ( expression in plasma cells from primary (AL) λ -J λ Analysis of V (2013) (0)
- [PP.33.16] IN RESTRICTIVE CARDIOMYOPATHY CAUSED BY CARDIAC AL AMYLOIDOSIS A RESTRICTIVE LV FILLING PATTERN IS ONLY PRESENT IN A MINORITY OF PATIENTS (2016) (0)
- Systemic Diseases (2010) (0)
- P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE (2022) (0)
- Continued effectiveness of eprodisate (NC-503) in the progression of AA amyloidosis-associated nephropathy : 3-year follow-up results (2007) (0)
- Electron microscopy and functional studies reveal cellular stress in amyloidogenic plasma cells (2013) (0)
- Crystal structure of the human beta-2 microglobulin mutant W60G (2008) (0)
- Be SMART About AL Amyloidosis. (2021) (0)
- AMYLOID-INDUCED MYOCARDIAL DYSFUNCTION DEPENDS ON THE BIOCHEMICAL CHARACTERISTICS OF THE AMYLOIDOGENIC PROTEIN AT COMPARABLE DEGRESS OF CARDIAC DEPOSITION: P2.112 (2004) (0)
- Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality (2013) (0)
- Beneficial Effects of Eprodisate (NC-503) for Patients with Amyloid A (AA) Amyloidosis: Results of a 2-Year, Multi-Center, Randomized, Placebo-Controlled Trial (2006) (0)
- Human Monoclonal Cryocrystalglobulinemia: First Complete Heavy and Light Chain Variable Region Nucleotide Sequences. (2004) (0)
- Rapid MALDI-TOF Method for Detecting and Isotyping M-Proteins: Evaluation of Paired Samples of Serum and Urine in Different Clinical Settings (2017) (0)
- Recommendations for the quantification of serum monoclonal components. (2015) (0)
- The low plasma concentration of amyloidogenic apolipoprotein A-I can be explained by a reduced efficiencyof its cellular secretion (2010) (0)
- Automated Processing of Serum Indices Used for Inter- Ference Detection by the Laboratory Information (0)
- Correction to: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization (2021) (0)
- ULTRASONIC TISSUE CHARACTERIZATION IN PATIENTS WITH INCREASED LEFT VENTRICULAR MASS DUE TO CARDIAC AL AMYLOIDOSIS: STRUCTURAL AND FUNCTIONAL PARAMETERS (2004) (0)
- Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study (2022) (0)
- Melphalan Plus High-Dose Dexamethasone in AL Patients Who are Not Candidates for Stem Cell Transplantation (2004) (0)
- Diflunisal in late-onset FAP patients with moderate to severe neuropathy (2015) (0)
- The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis (2023) (0)
- 37 P Familial mediterranean fever: Report of three Italian cases (2002) (0)
- 3 year follow-up results on a treatment for amyloid A (AA) amyloidosis (2006) (0)
- Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. (2023) (0)
- Characterization of anti-streptolysin O activity of a human monoclonal IgG lambda. (1987) (0)
- Regional cardiac uptake of 99-Tc-DPD is a novel powerful and independent prognostic marker in cardiac ATTR wild type amyloidosis (2020) (0)
- Abstract 18865: A Novel in vivo Model of Amyloidogenic Light Chain Induced Cardiac Toxicity in Zebrafish (2012) (0)
- High-Sensitivity Troponin Assay Improves the Detection of Cardiac Involvement in AL Amyloidosis and Is the Most Powerful Prognostic Determinant. (2009) (0)
- Management of Hematologic Malignancies: Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma (2010) (0)
- NOVEL DIAGNOSTIC TOOLS IN AMYLOIDOSIS (2012) (0)
- Use of 4'-iodo - 4 - deoxydoxorubicin for treatment of amyloidosis (1994) (0)
- Abstract 17139: Hereditary Transthyretin Amyloidosis With Exclusive Cardiac Phenotype: A Multicenter Italian Study (2010) (0)
- NT-proBNP after cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm (2005) (0)
- Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system (2017) (0)
- The second riboflavin-binding myeloma IgG lambdaDOT. I. Biochemical and functional characterization. (1990) (0)
- Familial myeloma. A new observation in two distinct pairs of siblings. (1985) (0)
- Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies (2022) (0)
- for a simple binary classification with clinical and investigational Study of prognosis in Waldenstrom's macroglobulinemia: a proposal (2011) (0)
- N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM) (2015) (0)
- PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY (2019) (0)
- [Determination of human serum ferritin by latex immunoassay]. (1984) (0)
- subcutaneous adipose tissue Reliable typing of systemic amyloidoses through proteomic analysis of (2012) (0)
- after chemotherapy best predicts survival in AL presentation and changes in N-terminal natriuretic peptide type B The combination of high-sensitivity cardiac troponin (2010) (0)
- CERTIFICATION REPORT The certification of the mass concentration of beta-2-microglobulin in human serum: ERM-DA470k/IFCC (2015) (0)
- Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients (2020) (0)
- Chapter 9 Waldenstrom ’ s Macrogloblinemia / Lymphoplasmacytic Lymphoma (0)
- Thalidomide Plus Intermediate-Dose Dexamethasone in Refractory/Relapsed AL Patients (2004) (0)
- PW02-021 - SAA1 is the strongest predictor of AA in TRAPS (2013) (0)
- study patients with relapsed systemic AL amyloidosis: results of a phase 1/2 Efficacy and safety of once-weekly and twice-weekly bortezomib in (2011) (0)
- Inherent cellular stress and exquisite proteasome sensitivity in amyloidogenic plasma cells (2014) (0)
- Diversity of amyloidosis in plasma cell dyscrasias：pathogenesis and therapy（REVIEW） (2016) (0)
- The patient with amyloidosis (2015) (0)
- Evaluation of a new ferritin reagent on the Olympus AU640. Abstr. (2003) (0)
- Non-tropical idiopathic splenomegaly. Report of a case. (1982) (0)
- Correction: Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients (2019) (0)
- Amyloid beta precursor protein (APP) mutations and apolipoprotein E alleles in italian patients affected by hereditary cerebral amyloid angiopathy (2004) (0)
- Measurement of ferritin using a new latex-enhanced immunoturbidimetric assay (2003) (0)
- Keynote Address: Advances in Systemic Amyloidoses: FROM MECHANISMS TO BETTER CARE (2007) (0)
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis (2021) (0)
- Malnutrition at Diagnosis Independently Predicts Mortality in Patients with Systemic Immunoglobulin Light-Chain Amyloidosis (AL) (2012) (0)
- Contents, Vol. 67, 1982 (1982) (0)
- OP0074 First Report of Circulating Micrornas in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) (2013) (0)
- Serum alpha-1-acid-glycoprotein, haptoglobin and C3 in Hodgkin's disease. A comparison with other acute-phase indicators. (1982) (0)
- A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family (2011) (0)
- Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) (2019) (0)
- Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone (2007) (0)
- Hereditary Cerebral Amyloid Angiopathy Associated with a Novel Amyloid Beta Precursor Protein Mutation (2004) (0)
- Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies (2021) (0)
- to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2— Evidence Base and Standardized Imaging Methods (2019) (0)
- Uncommon Conditions Underlying AA Amyloidosis (2004) (0)
- Waldenström's MacrogobulinemiaDecision Making and Problem Solving (2005) (0)
- 407 Mutations at position 385 within the hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) are rare and not restricted to patients with cryoglobulinemia (2004) (0)
- Slowing of renal function deterioration in AA amyloidosis patients treated with eprodisate: results after 3 year follow-up (2007) (0)
- Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy (2022) (0)
- 632 PREVALENCE OF VARIANT GENOTYPE IN PATIENTS WITH SUSPECTED CARDIAC ATTR AMYLOIDOSIS (2022) (0)
- New Insights Into a Multifaceted Disease. (2019) (0)
- Los componentes monoclonales (1988) (0)
- Predictive value of hCRP for recurrence in patients with persistent atrial fibrillation undergoing cardioversion (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Giampaolo Merlini?
Giampaolo Merlini is affiliated with the following schools:
